Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

RVNC SHAREHOLDERS: Robbins LLP Informs Investors of Class Action Against Revance Therapeutics, Inc. (RVNC)

Business Wire December 15, 2021

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) Investors

Business Wire December 15, 2021

DEADLINE: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RVNC

PR Newswire December 14, 2021

Revance Therapeutics Shareholder Alert

Newsfile December 14, 2021

ROSEN, A LONGSTANDING LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - RVNC

PR Newswire December 14, 2021

RVNC SECURITIES FRAUD: Hagens Berman, National Trial Attorneys, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed

PR Newswire December 14, 2021

RVNC Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Revance Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

PR Newswire December 14, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC

PR Newswire December 13, 2021

REVANCE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire December 13, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC

PR Newswire December 13, 2021

Revance Therapeutics Deadline Alert

Newsfile December 13, 2021

The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors

Business Wire December 13, 2021

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors

Business Wire December 13, 2021

Revance Therapeutics Investor Alert

Newsfile December 12, 2021

REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC

PR Newswire December 11, 2021

Revance Therapeutics Update

Newsfile December 11, 2021

Revance Therapeutics Shareholder Notice

Newsfile December 9, 2021

Revance Therapeutics Shareholder Alert

Newsfile December 8, 2021

Lost Money in Revance Therapeutics, Inc.?

Business Wire December 7, 2021

Revance Therapeutics Investor Alert

Newsfile December 7, 2021